System and method for inductively charging a medical device

Information

  • Patent Grant
  • 11872368
  • Patent Number
    11,872,368
  • Date Filed
    Wednesday, April 10, 2019
    5 years ago
  • Date Issued
    Tuesday, January 16, 2024
    4 months ago
Abstract
Methods and systems are disclosed wherein temperature in a device such as an ambulatory infusion pump is monitored during inductive charging of the device such that temperature-sensitive contents or components, such as, for example, insulin, particular circuitry and/or other components are not damaged. Temperature can be monitored in the device at one or more locations during inductive charging. If the temperature breaches one or more predetermined thresholds and/or is rising at a rate greater than one or more predetermined thresholds, charging can be suspended or provided at reduced power to prevent the temperature from further rising and damaging the contents and/or components of the device. One or more alerts associated with these events may also be triggered so that the user is aware of the situation and may take corrective action.
Description
TECHNICAL FIELD

The present disclosure relates to medical pumps for delivering medicament to a patient and, more specifically, to user-wearable infusion pumps for delivering medicament such as insulin to a patient.


BACKGROUND

There are many applications in academic, industrial, and medical fields that benefit from devices and methods that are capable of accurately and controllably delivering fluids, such as liquids and gases, that have a beneficial effect when administered in known and controlled quantities. Such devices and methods can be particularly useful in the medical field where treatments for many patients include the administration of a known amount of a substance at predetermined intervals.


One category of devices for delivering such fluids is that of pumps that have been developed for the administration of insulin and other medicaments for those suffering from both type I and type II diabetes. Some pumps configured as portable infusion devices can provide continuous subcutaneous medicament injection and/or infusion therapy for the treatment of diabetes. Such therapy may include, e.g., the regular and/or continuous injection or infusion of insulin into the skin of a person suffering from diabetes and offer an alternative to multiple daily injections of insulin by an insulin syringe or an insulin pen. Such pumps can be ambulatory/portable infusion pumps that are worn by the user and may use replaceable cartridges. Examples of such pumps and various features that can be associated with such pumps include those disclosed in U.S. Patent Application Publication No. 2013/0053816; U.S. Pat. Nos. 8,573,027; 8,986,253; U.S. Patent Application Publication No. 2013/0324928; U.S. Patent Application Publication No. 2013/0331790; U.S. Pat. No. 8,287,495; U.S. patent application Ser. No. 15/241,257 (filed Aug. 19, 2016); and U.S. patent application Ser. No. 15/158,125 (filed May 18, 2016), each of which is hereby incorporated herein by reference in its entirety.


Many ambulatory infusion pumps are powered by batteries that need to periodically be recharged. This is typically accomplished by inserting a connector of a cable into a port on the infusion pump (such as, e.g., a USB or similar port) that facilitates the transfer of power and/or data and plugging the other end of the cable into a wall outlet or other power source. Recently, a number of consumer devices have been developed that utilize electromagnetic induction to charge an internal battery of a device without the need for additional physical electrical connections. In such systems, a transmitting induction coil within a charging base creates an alternating electromagnetic field. When a receiving induction coil in the device is aligned with the transmitting induction coil, power is transferred to the device where it is used to charge the battery. Embodiments of portable infusion pumps that utilize inductive charging are disclosed in U.S. Patent Publication No. 2016/0339172 and U.S. patent application Ser. No. 15/868,461, each of which is hereby incorporated herein by reference in its entirety.


One of the challenges in enabling inductive charging, in particular with medical devices such as ambulatory infusion pumps, is that wireless charging can cause unwanted heating in electrically conductive materials, such as metals. This heating is caused by the electromagnetic induction of eddy currents generated in the metal. Excessive heating can become a problem particularly when the transmitting and receiving coils of the charging system are not optimally aligned. Unwanted heating can cause problems for medical devices that would not be an issue for typical consumer electronic devices such as smartphones. For example, medicaments such as insulin are temperature sensitive and can degrade and/or spoil if exposed to high temperatures. The possibility therefore exists that the insulin or other medicament in an infusion pump could spoil or otherwise be rendered ineffective or even dangerous while the device is inductively charging via such excessive heating. This possibility can be particularly troublesome if the pump user or caregiver is now aware that the insulin in the interior of the pump has been so affected, especially if no damage to the exterior of the pump or its circuitry or other internal components has been experienced.


SUMMARY

Methods and systems are disclosed wherein temperature in a device such as an ambulatory infusion pump is monitored during inductive charging of the device such that temperature-sensitive contents or components, such as, for example, insulin, particular circuitry and/or other components are not damaged. Temperature can be monitored in the device at one or more locations during inductive charging. If the temperature breaches one or more predetermined thresholds and/or is rising at a rate greater than one or more predetermined thresholds, charging can be suspended or provided at reduced power to prevent the temperature from further rising and damaging the contents and/or components of the device. One or more alerts associated with these events may also be triggered so that the user is aware of the situation and may take corrective action.


In an embodiment, a method includes detecting that an ambulatory infusion pump configured to contain a medicament and having a rechargeable battery has been placed on an inductive charging device and initiating charging of the rechargeable battery of the ambulatory infusion pump with the inductive charging device by transmitting power to the ambulatory infusion pump at a first charging rate. During charging a plurality of temperature values within the ambulatory infusion pump can be detected while power is transmitted to the ambulatory infusion pump at the first charging rate. The plurality of temperature values within the ambulatory infusion pump can be compared to a medicament sensitivity threshold temperature at which the medicament configured to be contained within the ambulatory infusion pump can become negatively affected by the temperature. If a temperature value of the plurality of temperature values within the ambulatory infusion pump is below the medicament sensitivity threshold temperature, the inductive charging device can continue to transmit power to the ambulatory infusion pump to at the first charging rate. If a temperature value of the plurality of temperature values within the ambulatory infusion pump is above the medicament sensitivity threshold temperature, the inductive charging device can reduce the first charging rate to a second charging rate lower than the first charging rate.


In an embodiment, an ambulatory infusion pump system can include an ambulatory infusion pump including a rechargeable battery and configured to contain a medicament, an inductive charging device configured to transmit power to the ambulatory infusion pump to charge the rechargeable battery of the ambulatory infusion pump and one or more processors. The system can be configured to detect that the ambulatory infusion pump has been placed on the inductive charging device and initiate charging of the rechargeable battery of the ambulatory infusion pump with the inductive charging device by transmitting power to the ambulatory infusion pump at a first charging rate. During charging a plurality of temperature values within the ambulatory infusion pump can be detected while power is transmitted to the ambulatory infusion pump at the first charging rate. The plurality of temperature values within the ambulatory infusion pump can be compared to a medicament sensitivity threshold temperature at which the medicament configured to be contained within the ambulatory infusion pump can become negatively affected by the temperature. If a temperature value of the plurality of temperature values within the ambulatory infusion pump is below the medicament sensitivity threshold temperature, the inductive charging device can continue to transmit power to the ambulatory infusion pump to at the first charging rate. If a temperature value of the plurality of temperature values within the ambulatory infusion pump is above the medicament sensitivity threshold temperature, the inductive charging device can reduce the first charging rate to a second charging rate lower than the first charging rate.


The above summary is not intended to describe each illustrated embodiment or every implementation of the subject matter hereof. The figures and the detailed description that follow more particularly exemplify various embodiments.





BRIEF DESCRIPTION OF THE DRAWINGS

Subject matter hereof may be more completely understood in consideration of the following detailed description of various embodiments in connection with the accompanying figures, in which:



FIG. 1A-1C depict a pump system according to an embodiment of the invention.



FIGS. 2A-2D depict a procedure for inductively charging a battery of a pump system according to an embodiment of the invention.



FIG. 3 depicts a flowchart of method steps for inductively charging a medical device according to embodiments of the invention.





While various embodiments are amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the claimed inventions to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the subject matter as defined by the claims.


DETAILED DESCRIPTION OF THE DRAWINGS


FIGS. 1A-1C depict a pump system including a pump 102 according to an embodiment of the invention. Drive unit 118 of pump 102 includes a drive mechanism 122 that mates with a recess in disposable cartridge 116 of pump 102 to attach the cartridge 116 to the drive unit 118 and provide for delivery of medicament such as insulin from the cartridge 116 to a user through a cannula. A pump system according to embodiments of the present invention can include a pump 102 including a drive unit 118 and a cartridge 116 as well as any additional components, such as for example, an infusion set. A short length of tubing 153 can extend from cartridge 116 with a connector 152 designed to attach to a corresponding connector of such an infusion set that includes a length of tubing extending from the corresponding connector to an infusion site having an infusion site connector to deliver medicament to the infusion site. Further details regarding such pumps can be found in U.S. patent application Ser. No. 14/707,851 filed May 8, 2015 and U.S. Patent Publication Nos. 2016/0339172 and 2017/0049957, each of which is hereby incorporated herein by reference in its entirety.


In one embodiment, pump 102 includes one or more processors that control operations of the pump and, in some embodiments, may receive information and/or commands from one or more separate devices. Such a separate device can include, for example, a dedicated remote control or a smartphone or other consumer electronic device executing an application configured to enable the device to transmit operating commands to the processor of pump 102. Other separate devices may include, e.g., a continuous glucose monitor (CGM), smart pen or other device designed to provide information about a user's blood glucose values or other relevant information about the user. In some embodiments, processor can also transmit information to one or more separate devices (such as, e.g., a smartphone, smartwatch, laptop or personal computer, table computer, CGM, etc.), such as information pertaining to device parameters, alarms, reminders, pump status, etc.


Referring to FIGS. 2A-2D, pumps according to embodiments of the present disclosure can include one or more rechargeable batteries in and/or associated with the pump drive unit 118. In some embodiments, a rechargeable battery can be inductively charged by, for example, an inductive charging pad 180. As depicted in FIG. 2B, in some embodiments, the charging pad 180 can include a cover 182 having a cutout sized to receive pump 102 in order to properly position and retain pump 102 on the charging pad 180 during recharging. In some embodiments, as shown in FIGS. 2A, 2B, 2D, the charging pad 180 may receive power by being connected to a wall outlet. In other embodiments, the charging pad 180 may additionally or alternatively include a power connection to, for example, a computer (e.g., via USB), a 12 volt automobile outlet, a battery pack (e.g., via USB), and a solar panel, among others.


To charge the pump 102, the pump 102 may first be disconnected from the tubing of the infusion set (as depicted in FIG. 2C). The pump can then be placed onto the charging pad 180 (as depicted in FIG. 2D), where its battery will automatically be inductively (re)charged when the pad 180 is connected to a power source. In another embodiment, the pump 102 can remain connected to the infusion set and the user while the battery is recharged. In some embodiments, a pump that can be inductively charged does not include a connection, such as a USB port, into which a power cord can be inserted for power transfer. Such an embodiment provides the advantages of being more robust for waterproofing because of the lack of exposed electrical contacts and obviating electrical isolation requirements imposed upon such connections.


Inductive charging of pump 102 can be carried out according to known standards, such as, for example, the Qi standard. In such a system, both the pump 102 and the charging pad 180 include an inductive coil. A transmitting coil in the charging pad 180 connected to the power source generates an oscillating magnetic field that induces an alternating current in a receiving coil in the pump 102 to transfer power to pump 102. In one embodiment, charging pad 180 is continuously or periodically (e.g., twice a second) sending an analog signal to detect the presence of a pump 102. When the pad detects the presence of a pump (via a magnetic load), it sends a digital communication signal to, e.g., a processor associated with the pump 102. The pump processor receives the signal and directs and/or sends a return signal to the pad 180, which causes the pad 180 to transmit charging power to the pump.


As noted above, such inductive charging can cause unwanted heating of devices when the batteries of those devices are charged. This issue is of particular concern with regard to devices that contain one or more heat-sensitive elements, components or contents such as medical devices including, for example, ambulatory infusion pumps that deliver one or more heat-sensitive medicaments such as insulin. Embodiments of the present invention therefore incorporate one or more temperature sensors to monitor an internal temperature in medical devices such as infusion pumps and can alter and/or suspend the inductive charging based on detected temperatures.


For example, in the case of insulin it is generally known that the critical temperature for stability of insulin is around 37 degrees Celsius. The system may therefore set a threshold temperature, such as, for example, 35 degrees Celsius, at or above which action to modify inductive charging will be taken and/or instructed to prevent the insulin from reaching 37 degrees. In one embodiment, the temperature sensor or sensors do not directly measure the temperature of the insulin or other medicament, but is/are instead located on a circuit board and measure the temperature of another element, such as a piece of metal, that directly contacts the insulin reservoir of the pump. One or more temperature sensors may in addition or alternatively be located on or near other heat-sensitive components or elements (such as, e.g., particular circuitry). The system can include an internal algorithm that converts the sensed temperature to an expected temperature of the insulin or other medicament or of the component or element of interest. Thus, when the present application refers to the system determining or measuring the temperature of the insulin or other medicament, component or element, the system may actually be measuring a temperature at a different location in the pump and converting the measurement, rather than directly measuring the temperature of the insulin or other medicament, component or element. The threshold temperature is thus directly related to a temperature that can negatively affect the medicament such as insulin, rather than a temperature that might affect the electronic or other components of the system.


The system can implement one or more of a number of procedures for preventing and/or reducing high temperatures when a temperature at or exceeding the temperature threshold is detected. There may be a single temperature sensor measuring a temperature at one location in the pump or a plurality of temperature sensors measuring temperatures in a plurality of locations. When a plurality of temperature sensors are employed, an alert may be triggered when an average of the temperature measurements exceeds a threshold or when a single temperature measurement exceeds a threshold. Temperatures may be obtained by the one or more temperature sensors and/or transmitted by the processor on a continuous basis or on a periodic basis, such as, for example, once every second, once or twice every minute, etc. Although primarily described with respect to measured temperature values exceeding a set threshold value, in some embodiments a rate of change of the measured temperature value or values can alternatively or additionally be employed in a similar fashion with respect to a threshold rate of change of temperature.


In one embodiment, when the measured temperature reaches or exceeds a preset temperature threshold (or rate of change of temperature threshold), inductive charging is disabled. This can be done by the pump sending a signal to the inductive charger to suspend charging by disabling electromagnetic power from being transmitted from the charging pad to the pump. If the pump is still connected to the user and delivering medicament, the medicament delivery can also be suspended. When the temperature has dropped to an acceptable charging level, inductive charging can be reactivated. In some embodiments, suspension of inductive charging and medicament delivery and reactivation of inductive charging can be provided in an automatic closed looped fashion. Such a closed loop system may also notify a user on a user interface of the pump and/or a remote control device of one or more of the actions taken by the system. For example, an alert may be presented on a user interface notifying the user that the inductive charging and/or insulin delivery has been suspended with a follow up alert when inductive charging and/or insulin delivery has been reinstituted. Such an alert may also include an auditory and/or vibratory notification. In a further embodiment, the system may require a user confirmation in response to one or more alerts prior to taking action, such as, for example, resuming inductive charging and/or medicament delivery.


In another embodiment, rather than completely disabling inductive charging when the system is at or above the threshold temperature (or rate of change of temperature), the system can instead lower the amount of electromagnetic power being transmitted by the charging pad (i.e. the charging rate). This can be accomplished by reducing the charging rate in the pump by a predetermined amount. The charging rate can be increased once the temperature has been lowered by a desired amount. If the pump is currently delivering medicament, in some embodiments the system can disable medicament delivery when the charging rate is reduced and resume delivery when increased charging is resumed. One or more alerts may further be provided relating to the actions taken by the system. The system can, in various embodiments, undertake one or more actions automatically or may require user confirmation before undertaking one or more actions. In some embodiments, if the temperature continues to rise or is not reduced at a desired rate and/or amount, the charging rate can be further reduced or completely disabled.


Reduced charging provides the advantage over suspending charging that the device will still be continuously charged, though the temperature will not be reduced as fast under reduced charging as when charging is completely disabled. Although reduction of the charging rate has been described as an alternative to completely suspending charging, it should be understood that these two approaches could be employed together during a single charging process, in an alternating or otherwise periodically rotating manner. For example, in one embodiment charging can be reduced if the temperature exceeds a first threshold temperature and suspended if the temperature exceeds a second, higher threshold temperature. In other embodiments, suspending charging and reducing charging may be alternated or otherwise periodically rotated, as in some instances continuous reduced charging may charge the battery faster and in other instances utilizing full power charging for periods with periods of suspended charging may charge the battery faster.


One or more additional notifications may be provided to the user by the system either concurrently with or independently of the notifications of the suspension or reduction of charging and/or other notifications described herein. For example, whether charging is intermittently disabled or the charging rate is reduced, the pump will take longer than typical to charge. The user can therefore additionally be notified that the battery may take longer than expected to charge. In addition, a high temperature and/or high rate of change of temperature may indicate improper alignment of the transmitting coil in the charging pad and receiving coil in the pump. The user may therefore alternatively or additionally be notified that there may be improper alignment and to check the alignment. Repeated temperature alarms may indicate an issue with the charging pad and therefore after a threshold number of alarms the user can be notified that the charging pad may be damaged and to replace the charging pad. In addition, when the temperature has exceeded the threshold temperature and/or reach an even higher threshold (e.g., 37 degrees Celsius for insulin), the user can be notified that the insulin or other medicament may have degraded and/or spoiled. Any of the alarms and alerts described herein can further include instructions to the user to take an action with respect to the notification. For example, in various embodiments the user can be instructed to check the alignment of the pump with respect to the charging pad, use a different charging pad, etc. in conjunction with a corresponding notification.


Detailed notifications such as those described above can be provided to the user on a user interface of a device, such as, for example, the pump, a dedicated remote controller and/or a remote consumer electronic device having a software application for controlling the pump, such as a smartphone. In addition, one or more of the pump or charging pad can include an indicator light thereon. Issues with inductive charging can alternatively or additionally be indicated by such an indicator light by, for example, the light going from off to on, the light blinking, the light blinking at a different rate, the light changing color, the light brightness changing, etc. In some embodiments, different indicator light actions (e.g., different rates of blinking) can indicate different charging issues or actions (e.g., charging suspended or charging power reduced).


Although the system is primarily described herein as suspending and/or modifying an ongoing inductive charging based on temperature measurements, there may also be circumstances where the pump is initially placed on the charger at an already elevated temperature. In such circumstances, the initial charging can be reduced, not initiated, etc. and alerts provided as described herein with respect to suspension or modification of ongoing charging.


Referring now to FIG. 3, a flowchart of methods 200 for inductively charging a medical device such as an ambulatory infusion pump that incorporates temperature monitoring is depicted. At step 202, the device is placed on the charger and the charging pad detects the device at step 203. In some embodiments, the temperature of the device is determined as described herein and compared to one or more threshold temperatures before charging is initiated at step 204. If the temperature is above a predetermined threshold, charging can alternatively not be initiated at step 206 or initiated at reduced power at step 208. With either approach, in some embodiments the user can then be notified of the action taken at step 210 or step 212. Alternatively, the corresponding action can be taken without user notification (as indicated by the dashed arrows). In various embodiments, the system can then revert to step 204 and continue to continuously or periodically monitor the temperature. If charging was reduced, upon a further increase in temperature or if the temperature is not lowering at a desired rate and/or amount, the charging may be further reduced or disabled. This may be done automatically or may be done after the user acknowledges the alert, for example.


If it is determined that the temperature is below the predetermined threshold, either initially or after clearing an alert, full power charging is initiated to charge the device at step 214. In some embodiments, the user can be notified that charging has been initiated. During charging, the temperature can be monitored and compared to a predetermined threshold, which may be the same or different from the threshold in step 204, on a periodic or continuous basis at step 216. If the temperature is below the predetermined threshold, full power charging continues and the system continues to monitor the temperature. If the temperature is above the predetermined threshold, charging can alternatively be suspended at step 218 or continued at a reduced power at step 220. The user can be notified that charging has been suspended at step 222 or reduced at step 224, respectively, and in some embodiments can further be notified that charging has been initiated (at reduced power) at step 224. Alternatively, the corresponding action can be taken without user notification (as indicated by the dashed arrows). The system can then continue to monitor the temperature at step 216, either automatically or in response to a user confirmation, and reinitiate full power charging when the temperature falls below the predetermined temperature in response to the suspended or reduced power charging. If charging was initially reduced and the temperature either continues to increase or not lowering at a desired rate and/or amount, the charging may be further reduced or disabled. The above steps can continue until the device battery is fully charged or until the device is otherwise removed from the charger.


In embodiments, the system determinations described above can all be made by a processor of the infusion pump. For example, the infusion pump can measure the temperatures, compare the temperatures and cause the inductive charger to disable and/or modulate the transmitted power by sending control signals to the pad that cause the processor of the pad to adjust the power according to the control signal. In other embodiments, one or more of these determinations can be made by a processor of the inductive charging pad or a separate device in communication with the pump, such as a remote control device.


Although the systems and methods have primarily been described herein as applying to an infusion pump for delivering a liquid medicament such as an ambulatory insulin pump, it should be understood that the systems and methods herein can be employed with any device that can utilize inductive charging to recharge an internal battery and includes one or more heat sensitive elements.


Also incorporated herein by reference in their entirety are commonly owned U.S. Pat. Nos. 8,287,495; 8,408,421 8,448,824; 8,573,027; 8,650,937; 8,986,523; 9,173,998; 9,180,242; 9,180,243; 9,238,100; 9,242,043; 9,335,910; 9,381,271; 9,421,329; 9,486,171; 9,486,571; 9,492,608; 9,503,526; 9,555,186; 9,565,718; 9,603,995; 9,669,160; 9,715,327; 9,737,656; 9,750,871; 9,867,937; 9,867,953; 9,940,441; 9,993,595; 10,016,561; 10,201,656, commonly owned U.S. Patent Publication Nos. 2009/0287180; 2012/0123230; 2013/0053816; 2014/0276419; 2014/0276423; 2014/0276569; 2014/0276570; 2015/0182693; 2016/0082188; 2016/0339172; 2017/0049957; 2017/0142658; 2017/0182248; 2017/0250971; 2018/0021514; 2018/0071454; and 2018/0193555 and commonly owned U.S. patent application Ser. Nos. 14/707,851 and 16/266,471.


Further incorporated by reference herein in their entirety are U.S. Pat. Nos. 8,601,465; 8,502,662; 8,452,953; 8,451,230; 8,449,523; 8,444,595; 8,343,092; 8,285,328; 8,126,728; 8,117,481; 8,095,123; 7,999,674; 7,819,843; 7,782,192; 7,109,878; 6,997,920; 6,979,326; 6,936,029; 6,872,200; 6,813,519; 6,641,533; 6,554,798; 6,551,276; 6,295,506; and 5,665,065.


Various embodiments of systems, devices, and methods have been described herein. These embodiments are given only by way of example and are not intended to limit the scope of the claimed inventions. It should be appreciated, moreover, that the various features of the embodiments that have been described may be combined in various ways to produce numerous additional embodiments. Moreover, while various materials, dimensions, shapes, configurations and locations, etc. have been described for use with disclosed embodiments, others besides those disclosed may be utilized without exceeding the scope of the claimed inventions.


Persons of ordinary skill in the relevant arts will recognize that the subject matter hereof may comprise fewer features than illustrated in any individual embodiment described above. The embodiments described herein are not meant to be an exhaustive presentation of the ways in which the various features of the subject matter hereof may be combined. Accordingly, the embodiments are not mutually exclusive combinations of features; rather, the various embodiments can comprise a combination of different individual features selected from different individual embodiments, as understood by persons of ordinary skill in the art. Moreover, elements described with respect to one embodiment can be implemented in other embodiments even when not described in such embodiments unless otherwise noted.


Although a dependent claim may refer in the claims to a specific combination with one or more other claims, other embodiments can also include a combination of the dependent claim with the subject matter of each other dependent claim or a combination of one or more features with other dependent or independent claims. Such combinations are proposed herein unless it is stated that a specific combination is not intended.


Any incorporation by reference of documents above is limited such that no subject matter is incorporated that is contrary to the explicit disclosure herein. Any incorporation by reference of documents above is further limited such that no claims included in the documents are incorporated by reference herein. Any incorporation by reference of documents above is yet further limited such that any definitions provided in the documents are not incorporated by reference herein unless expressly included herein.


For purposes of interpreting the claims, it is expressly intended that the provisions of 35 U.S.C. § 112(f) are not to be invoked unless the specific terms “means for” or “step for” are recited in a claim.

Claims
  • 1. A method, comprising: detecting that an ambulatory infusion pump configured to contain a medicament and having a rechargeable battery has been placed on an inductive charging device;initiating charging of the rechargeable battery of the ambulatory infusion pump with the inductive charging device by transmitting power to the ambulatory infusion pump at a first charging rate;detecting a plurality of temperature values within the ambulatory infusion pump while transmitting power to the ambulatory infusion pump at the first charging rate;determining a rate of change of the plurality of temperature values;comparing the plurality of temperature values and the rate of change of the plurality of temperature values within the ambulatory infusion pump to one or more predetermined thresholds relating to a medicament sensitivity threshold temperature, the medicament sensitivity threshold temperature being a temperature at which the medicament configured to be contained within the ambulatory infusion pump can become negatively affected by the temperature; andif a temperature value of the plurality of temperature values and the rate of change of the plurality of temperature values within the ambulatory infusion pump is below the one or more predetermined thresholds, causing the inductive charging device to continue to transmit power to the ambulatory infusion pump at the first charging rate, andif one or more of the temperature value of the plurality of temperature values and the rate of change of the plurality of temperature values within the ambulatory infusion pump is above a first threshold of the one or more predetermined thresholds and below a second threshold of the one or more predetermined thresholds higher than the first threshold, causing the inductive charging device to reduce the first charging rate to a second charging rate lower than the first charging rate, andif one or more of the temperature values of the plurality of temperature values and the rate of change of the plurality of temperature values within the ambulatory infusion pump is above the second threshold higher than the first threshold, causing the inductive charging device to suspend charging of the ambulatory infusion pump.
  • 2. The method of claim 1, wherein the second charging rate is a reduced, non-zero charging rate less than the first charging rate.
  • 3. The method of claim 1, wherein the first charging rate is a maximum charging rate that the inductive charging device can provide.
  • 4. The method of claim 1, further comprising determining a temperature value within the ambulatory infusion pump before initiating charging of the rechargeable battery and only initiating charging if the temperature value is below the medicament sensitivity threshold temperature.
  • 5. The method of claim 4, further comprising providing a notification to a user that charging has not been initiated if the temperature within the ambulatory infusion pump is above the medicament sensitivity threshold temperature.
  • 6. The method of claim 1, further comprising determining a temperature value within the ambulatory infusion pump before initiating charging of the rechargeable battery and initiating charging at the second charging rate rather than the first charging rate if the temperature value is above the medicament sensitivity threshold temperature.
  • 7. The method of claim 1, further comprising providing a notification to a user that the charging rate has been reduced to the second charging rate.
  • 8. The method of claim 1, further comprising increasing the charging rate to the first charging rate if one of the plurality of temperatures values and the rate of change of the plurality of temperature values is below the one or more predetermined thresholds while the inductive charging device is transmitting power at the second charging rate.
  • 9. The method of claim 1, further comprising suspending delivery of the medicament with the ambulatory infusion pump if one or more of the temperature value of the plurality of temperature values and the rate of change of the plurality of temperature values within the ambulatory infusion pump is above the one or more predetermined thresholds.
  • 10. The method of claim 1, further comprising providing a notification to the user on a user interface of the ambulatory infusion pump or a remote control device to check alignment of the ambulatory infusion pump on the inductive charging device if one or more of the temperature value of the plurality of temperature values and the rate of change of the plurality of temperature values within the ambulatory infusion pump is above the first threshold or the second threshold.
RELATED APPLICATION

The present application claims the benefit of U.S. Provisional Application No. 62/655,516 filed Apr. 10, 2018, which is hereby incorporated herein in its entirety by reference.

US Referenced Citations (380)
Number Name Date Kind
4393365 Kondo et al. Jul 1983 A
4475901 Kraegen et al. Oct 1984 A
4678460 Rosner Jul 1987 A
5104374 Bishko et al. Apr 1992 A
5122362 Phillips et al. Jun 1992 A
5181910 Scanlon Jan 1993 A
5311175 Waldman May 1994 A
5338157 Blomquist Aug 1994 A
5364346 Schrezenmeir Nov 1994 A
5368562 Blomquist et al. Nov 1994 A
5389078 Zalesky et al. Feb 1995 A
5485408 Blomquist Jan 1996 A
5569186 Lord et al. Oct 1996 A
5641405 Keshaviah et al. Jun 1997 A
5658250 Blomquist et al. Aug 1997 A
5658252 Johnson Aug 1997 A
5665065 Colman et al. Sep 1997 A
5669877 Blomquist Sep 1997 A
5685844 Marttila Nov 1997 A
5690693 Wang Nov 1997 A
5695473 Olsen Dec 1997 A
5713856 Eggers et al. Feb 1998 A
5782805 Meinzer et al. Jul 1998 A
5810771 Blomquist Sep 1998 A
5814015 Gargano et al. Sep 1998 A
5822715 Worthington et al. Oct 1998 A
5876370 Blomquist Mar 1999 A
5879143 Cote et al. Mar 1999 A
5935099 Peterson et al. Aug 1999 A
5935106 Olsen Aug 1999 A
5997475 Bortz Dec 1999 A
6024539 Blomquist Feb 2000 A
6077055 Vilks Jun 2000 A
6122536 Sun et al. Sep 2000 A
6241704 Peterson et al. Jun 2001 B1
6248057 Mavity et al. Jun 2001 B1
6248067 Causey, III et al. Jun 2001 B1
6368272 Porumbescu Apr 2002 B1
6379301 Worthington et al. Apr 2002 B1
6422057 Anderson Jul 2002 B1
6475180 Peterson et al. Nov 2002 B2
6544212 Galley et al. Apr 2003 B2
6551276 Mann et al. Apr 2003 B1
6554798 Mann et al. Apr 2003 B1
6558320 Causey, III et al. May 2003 B1
6558351 Steil et al. May 2003 B1
6562001 Lebel et al. May 2003 B2
6571128 Lebel et al. May 2003 B2
6577899 Lebel et al. Jun 2003 B2
6582366 Porumbescu Jun 2003 B1
6641533 Causey, III et al. Nov 2003 B2
6648821 Lebel et al. Nov 2003 B2
6656114 Poulsen et al. Dec 2003 B1
6731976 Penn et al. May 2004 B2
6740072 Starkweather et al. May 2004 B2
6744350 Blomquist Jun 2004 B2
6790198 White et al. Sep 2004 B1
6809653 Mann et al. Oct 2004 B1
6835175 Porumbescu Dec 2004 B1
6852104 Blomquist Feb 2005 B2
6862466 Ackerman Mar 2005 B2
6872200 Mann et al. Mar 2005 B2
6873268 Lebel et al. Mar 2005 B2
6934220 Cruitt et al. Aug 2005 B1
6936029 Mann et al. Aug 2005 B2
6958705 Lebel et al. Oct 2005 B2
6974437 Lebel et al. Dec 2005 B2
6979326 Mann et al. Dec 2005 B2
6997920 Mann et al. Feb 2006 B2
6998387 Goke et al. Feb 2006 B1
7025743 Mann et al. Apr 2006 B2
7033338 Vilks et al. Apr 2006 B2
7041082 Blomquist et al. May 2006 B2
7098803 Mann et al. Aug 2006 B2
7107706 Bailey, Sr. et al. Sep 2006 B1
7109878 Mann et al. Sep 2006 B2
7136701 Greatbatch et al. Nov 2006 B2
7137951 Pilarski Nov 2006 B2
7179226 Crothall et al. Feb 2007 B2
7200504 Fister Apr 2007 B1
7258864 Clark Aug 2007 B2
7267665 Steil et al. Sep 2007 B2
7276057 Gerber Oct 2007 B2
7278983 Ireland et al. Oct 2007 B2
7282029 Poulsen et al. Oct 2007 B1
7291107 Hellwig et al. Nov 2007 B2
7307245 Faries, Jr. et al. Dec 2007 B2
7324012 Mann et al. Jan 2008 B2
7341577 Gill Mar 2008 B2
7354420 Steil et al. Apr 2008 B2
7399277 Saidara et al. Jul 2008 B2
7402153 Steil et al. Jul 2008 B2
7404796 Ginsberg Jul 2008 B2
7440806 Whitehurst et al. Oct 2008 B1
7481759 Whitehurst et al. Jan 2009 B2
7493171 Whitehurst et al. Feb 2009 B1
7515060 Blomquist Apr 2009 B2
7517530 Clark Apr 2009 B2
7556841 Kimball et al. Jul 2009 B2
7558629 Keimel et al. Jul 2009 B2
7559926 Blischak Jul 2009 B1
7572789 Cowen et al. Aug 2009 B2
7651845 Doyle, III et al. Jan 2010 B2
7678071 Lebel et al. Mar 2010 B2
7704226 Mueller, Jr. et al. Apr 2010 B2
7704227 Moberg et al. Apr 2010 B2
7715893 Kamath et al. May 2010 B2
7734323 Blomquist et al. Jun 2010 B2
7751907 Blomquist Jul 2010 B2
7806886 Kanderian, Jr. et al. Oct 2010 B2
7831310 Lebel et al. Nov 2010 B2
7869851 Hellwig et al. Jan 2011 B2
7912674 Killoren Clark et al. Mar 2011 B2
7935076 Estes et al. May 2011 B2
7959598 Estes Jun 2011 B2
7972296 Braig et al. Jul 2011 B2
7981034 Jennewine et al. Jul 2011 B2
7988630 Osorio et al. Aug 2011 B1
8030802 Lindegger et al. Oct 2011 B2
8082041 Radziemski Dec 2011 B1
8100852 Moberg et al. Jan 2012 B2
8119593 Richardson et al. Feb 2012 B2
8152789 Starkweather et al. Apr 2012 B2
8170721 Nickerson May 2012 B2
8192394 Estes et al. Jun 2012 B2
8192395 Estes et al. Jun 2012 B2
8204729 Sher Jun 2012 B2
8206350 Mann et al. Jun 2012 B2
8206378 Kalpin et al. Jun 2012 B1
8208984 Blomquist et al. Jun 2012 B2
8221346 Sakata et al. Jul 2012 B2
8226891 Sloan et al. Jul 2012 B2
8231562 Buck et al. Jul 2012 B2
8246540 Ginsberg Aug 2012 B2
8287454 Wolpert et al. Oct 2012 B2
8287495 Michaud et al. Oct 2012 B2
8326546 Stewart et al. Dec 2012 B2
8328754 Estes et al. Dec 2012 B2
8348886 Kanderian, Jr. et al. Jan 2013 B2
8348923 Kanderian, Jr. et al. Jan 2013 B2
8376943 Kovach et al. Feb 2013 B2
8414523 Blomquist et al. Apr 2013 B2
8454510 Yodfat et al. Jun 2013 B2
8457758 Olson Jun 2013 B2
8465460 Yodfat et al. Jun 2013 B2
8573027 Rosinko et al. Nov 2013 B2
8938306 Lebel Jan 2015 B2
8986253 Lebel et al. Jan 2015 B2
9259531 Kamen Feb 2016 B2
9381297 Brown et al. Jul 2016 B2
9889250 Blomquist et al. Feb 2018 B2
9974903 Davis May 2018 B1
9993595 Michaud et al. Jun 2018 B2
10279106 Cook et al. May 2019 B1
10279107 Michael May 2019 B2
10357603 Michaud et al. Jul 2019 B2
10438696 Shapley et al. Oct 2019 B2
10777319 Shapley et al. Sep 2020 B2
20010031944 Peterson et al. Oct 2001 A1
20010037217 Abensour et al. Nov 2001 A1
20020002326 Causey, III et al. Jan 2002 A1
20020016568 Lebel Feb 2002 A1
20020019606 Lebel Feb 2002 A1
20020065454 Lebel et al. May 2002 A1
20020072733 Flaherty Jun 2002 A1
20020072932 Swamy Jun 2002 A1
20020096543 Juselius Jul 2002 A1
20020107476 Mann et al. Aug 2002 A1
20020143580 Bristol et al. Oct 2002 A1
20020183693 Peterson et al. Dec 2002 A1
20020193679 Malave et al. Dec 2002 A1
20030032867 Crothall et al. Feb 2003 A1
20030036683 Kehr et al. Feb 2003 A1
20030050621 Lebel et al. Mar 2003 A1
20030060765 Campbell et al. Mar 2003 A1
20030065308 Lebel et al. Apr 2003 A1
20030088238 Poulsen et al. May 2003 A1
20030114836 Estes et al. Jun 2003 A1
20030130616 Steil et al. Jul 2003 A1
20030160683 Blomquist Aug 2003 A1
20030163088 Blomquist Aug 2003 A1
20030163090 Blomquist et al. Aug 2003 A1
20030208113 Mault et al. Nov 2003 A1
20030212364 Mann et al. Nov 2003 A1
20030212379 Bylund et al. Nov 2003 A1
20030225396 Cartledge et al. Dec 2003 A1
20030236489 Jacobson et al. Dec 2003 A1
20040015102 Cummings et al. Jan 2004 A1
20040059295 Cartledge et al. Mar 2004 A1
20040068230 Estes et al. Apr 2004 A1
20040073095 Causey, III et al. Apr 2004 A1
20040115067 Rush et al. Jun 2004 A1
20040176720 Kipfer Sep 2004 A1
20040180810 Pilarski Sep 2004 A1
20040220517 Starkweather et al. Nov 2004 A1
20040254434 Goodnow et al. Dec 2004 A1
20050021006 Tonnies Jan 2005 A1
20050022274 Campbell et al. Jan 2005 A1
20050030164 Blomquist Feb 2005 A1
20050050621 Thomas Mar 2005 A1
20050060030 Lashinski et al. Mar 2005 A1
20050065760 Murtfeldt et al. Mar 2005 A1
20050085760 Ware et al. Apr 2005 A1
20050095063 Fathallah et al. May 2005 A1
20050137530 Campbell et al. Jun 2005 A1
20050143864 Blomquist Jun 2005 A1
20050171513 Mann et al. Aug 2005 A1
20050177137 Kipfer Aug 2005 A1
20050197553 Cooper Sep 2005 A1
20050197621 Poulsen et al. Sep 2005 A1
20050277872 Colby, Jr. et al. Dec 2005 A1
20060001550 Mann et al. Jan 2006 A1
20060014670 Green et al. Jan 2006 A1
20060047192 Hellwig et al. Mar 2006 A1
20060047538 Condurso et al. Mar 2006 A1
20060080059 Stupp et al. Apr 2006 A1
20060122577 Poulsen et al. Jun 2006 A1
20060132292 Blomquist Jun 2006 A1
20060137695 Hellwig et al. Jun 2006 A1
20060149220 Ullestad et al. Jul 2006 A1
20060173406 Hayes et al. Aug 2006 A1
20060173444 Choy et al. Aug 2006 A1
20060202859 Mastrototaro et al. Sep 2006 A1
20060224109 Steil et al. Oct 2006 A1
20060253097 Braig et al. Nov 2006 A1
20060264895 Flanders Nov 2006 A1
20060276771 Galley et al. Dec 2006 A1
20070016127 Staib et al. Jan 2007 A1
20070016449 Cohen et al. Jan 2007 A1
20070021733 Hansen et al. Jan 2007 A1
20070033074 Nitzan et al. Feb 2007 A1
20070060796 Kim Mar 2007 A1
20070060871 Istoc et al. Mar 2007 A1
20070061735 Hoffberg et al. Mar 2007 A1
20070066956 Finkel Mar 2007 A1
20070100222 Mastrototaro et al. May 2007 A1
20070106135 Sloan et al. May 2007 A1
20070112299 Smit et al. May 2007 A1
20070124002 Estes et al. May 2007 A1
20070156033 Causey, III et al. Jul 2007 A1
20070203454 Shermer et al. Aug 2007 A1
20070219480 Kamen et al. Sep 2007 A1
20070219496 Kamen et al. Sep 2007 A1
20070219597 Kamen et al. Sep 2007 A1
20070228071 Kamen et al. Oct 2007 A1
20070233051 Hohl et al. Oct 2007 A1
20070239096 Keenan et al. Oct 2007 A1
20070255250 Moberg et al. Nov 2007 A1
20080004601 Jennewine et al. Jan 2008 A1
20080017194 Hassanein et al. Jan 2008 A1
20080030369 Mann et al. Feb 2008 A1
20080033357 Mann et al. Feb 2008 A1
20080051709 Mounce et al. Feb 2008 A1
20080051714 Moberg et al. Feb 2008 A1
20080071251 Moubayed et al. Mar 2008 A1
20080071580 Marcus et al. Mar 2008 A1
20080097289 Steil et al. Apr 2008 A1
20080106431 Blomquist May 2008 A1
20080125700 Moberg et al. May 2008 A1
20080125701 Moberg et al. May 2008 A1
20080147050 Mann et al. Jun 2008 A1
20080172026 Blomquist Jul 2008 A1
20080172027 Blomquist Jul 2008 A1
20080172028 Blomquist Jul 2008 A1
20080172029 Blomquist Jul 2008 A1
20080172030 Blomquist Jul 2008 A1
20080172031 Blomquist Jul 2008 A1
20080177165 Blomquist et al. Jul 2008 A1
20080183060 Steil et al. Jul 2008 A1
20080206799 Blomquist Aug 2008 A1
20080228056 Blomquist et al. Sep 2008 A1
20080262378 Gerber et al. Oct 2008 A1
20080262380 Gerber et al. Oct 2008 A1
20080262878 Gerber et al. Oct 2008 A1
20080269585 Ginsberg Oct 2008 A1
20080281297 Pesach et al. Nov 2008 A1
20080287922 Panduro Nov 2008 A1
20080294024 Cosentino Nov 2008 A1
20080294294 Blomquist Nov 2008 A1
20080300534 Blomquist Dec 2008 A1
20080300572 Rankers et al. Dec 2008 A1
20080306353 Douglas et al. Dec 2008 A1
20080312723 Gill et al. Dec 2008 A1
20090005724 Regittnig Jan 2009 A1
20090005726 Jones et al. Jan 2009 A1
20090018779 Cohen et al. Jan 2009 A1
20090030733 Cohen et al. Jan 2009 A1
20090036753 King Feb 2009 A1
20090069749 Miller et al. Mar 2009 A1
20090069787 Estes et al. Mar 2009 A1
20090088731 Campbell et al. Apr 2009 A1
20090105646 Hendrixson et al. Apr 2009 A1
20090112626 Talbot et al. Apr 2009 A1
20090131860 Nielsen May 2009 A1
20090131861 Braig et al. May 2009 A1
20090150186 Cohen et al. Jun 2009 A1
20090177142 Blomquist et al. Jul 2009 A1
20090177147 Blomquist et al. Jul 2009 A1
20090177154 Blomquist Jul 2009 A1
20090212966 Panduro Aug 2009 A1
20090240193 Mensinger et al. Sep 2009 A1
20090254037 Bryant, Jr. et al. Oct 2009 A1
20100056993 Chase Mar 2010 A1
20100057043 Kovatchev et al. Mar 2010 A1
20100114015 Kanderian, Jr. et al. May 2010 A1
20100121415 Skelton et al. May 2010 A1
20100138197 Sher Jun 2010 A1
20100145262 Bengtsson et al. Jun 2010 A1
20100145303 Yodfat et al. Jun 2010 A1
20100152644 Pesach et al. Jun 2010 A1
20100152811 Flaherty Jun 2010 A1
20100156633 Buck, Jr. et al. Jun 2010 A1
20100174266 Estes Jul 2010 A1
20100198142 Sloan et al. Aug 2010 A1
20100198520 Breton et al. Aug 2010 A1
20100218132 Soni et al. Aug 2010 A1
20100222765 Blomquist et al. Sep 2010 A1
20100262117 Magni et al. Oct 2010 A1
20100262434 Shaya Oct 2010 A1
20100274592 Nitzan et al. Oct 2010 A1
20100274751 Blomquist Oct 2010 A1
20100292634 Kircher, Jr. et al. Nov 2010 A1
20100295686 Sloan et al. Nov 2010 A1
20100305545 Kanderian, Jr. et al. Dec 2010 A1
20100312085 Andrews et al. Dec 2010 A1
20100324382 Cantwell et al. Dec 2010 A1
20110009824 Yodfat et al. Jan 2011 A1
20110021898 Wei et al. Jan 2011 A1
20110033833 Blomquist et al. Feb 2011 A1
20110040247 Mandro et al. Feb 2011 A1
20110040251 Blomquist et al. Feb 2011 A1
20110046697 Gerber et al. Feb 2011 A1
20110047499 Mandro et al. Feb 2011 A1
20110053121 Heaton Mar 2011 A1
20110054390 Searle et al. Mar 2011 A1
20110058485 Sloan Mar 2011 A1
20110071765 Yodfat et al. Mar 2011 A1
20110092788 Long et al. Apr 2011 A1
20110098548 Budiman et al. Apr 2011 A1
20110106011 Cinar et al. May 2011 A1
20110106050 Yodfat et al. May 2011 A1
20110112505 Starkweather et al. May 2011 A1
20110112506 Starkweather et al. May 2011 A1
20110125095 Lebel et al. May 2011 A1
20110160695 Sigrist et al. Jun 2011 A1
20110172744 Davis et al. Jul 2011 A1
20110178717 Goodnow et al. Jul 2011 A1
20110190701 Remde et al. Aug 2011 A1
20110196213 Thukral et al. Aug 2011 A1
20110205065 Strachan et al. Aug 2011 A1
20110208155 Palerm et al. Aug 2011 A1
20110238033 Prod et al. Sep 2011 A1
20110257591 Nelson Konen Oct 2011 A1
20120041415 Estes et al. Feb 2012 A1
20120059353 Kovatchev et al. Mar 2012 A1
20120059673 Cohen et al. Mar 2012 A1
20120078181 Smith et al. Mar 2012 A1
20120184907 Smith Jul 2012 A1
20120185267 Kamen et al. Jul 2012 A1
20120191061 Yodfat et al. Jul 2012 A1
20120191063 Brauker et al. Jul 2012 A1
20120209165 Degen et al. Aug 2012 A1
20120232520 Sloan et al. Sep 2012 A1
20120302991 Blomquist et al. Nov 2012 A1
20130046281 Javitt Feb 2013 A1
20130053816 Diperna et al. Feb 2013 A1
20130238048 Almendinger Sep 2013 A1
20130324928 Kruse Dec 2013 A1
20130331790 Brown et al. Dec 2013 A1
20140012511 Mensinger et al. Jan 2014 A1
20140070761 Labbe Mar 2014 A1
20140187890 Mensinger Jul 2014 A1
20140266022 Degen et al. Sep 2014 A1
20140323961 Blomquist et al. Oct 2014 A1
20150196709 Jacobson et al. Jul 2015 A1
20160213843 Despa Jul 2016 A1
20160339172 Michaud et al. Nov 2016 A1
20170049957 Michaud Feb 2017 A1
20170142658 Kruse May 2017 A1
20190190296 Paralikar Jun 2019 A1
Foreign Referenced Citations (33)
Number Date Country
4407005 Mar 1995 DE
10121317 Nov 2002 DE
10352456 Jul 2005 DE
1102194 May 2001 EP
1571582 Sep 2005 EP
1904153 Apr 2015 EP
WO-0045696 Aug 2000 WO
WO-0074753 Dec 2000 WO
WO-0152727 Jul 2001 WO
WO-02062212 Aug 2002 WO
WO-2005018507 Mar 2005 WO
WO-2005046559 May 2005 WO
WO-2006061169 Jun 2006 WO
WO-2007000425 Jan 2007 WO
WO-2007056592 May 2007 WO
WO-2007089537 Aug 2007 WO
WO-2007149533 Dec 2007 WO
WO-2008048556 Apr 2008 WO
WO-2008048582 Apr 2008 WO
WO-2008048583 Apr 2008 WO
WO-2008048584 Apr 2008 WO
WO-2008048585 Apr 2008 WO
WO-2008048586 Apr 2008 WO
WO-2008048587 Apr 2008 WO
WO-2008091320 Jul 2008 WO
WO-2008112078 Sep 2008 WO
WO-2008153689 Dec 2008 WO
WO-2008153819 Dec 2008 WO
WO-2009035759 Mar 2009 WO
WO-2009088983 Jul 2009 WO
WO-2009089028 Jul 2009 WO
WO-2009089029 Jul 2009 WO
WO-2010096449 Aug 2010 WO
Non-Patent Literature Citations (22)
Entry
Application and File history for U.S. Patent Application No. U.S. Appl. No. 14/317,751, filed Jun. 27, 2014 . . . Inventors: Blomquist et al.
Search report and Written Opinion dated Jul. 15, 2019 for PCT Application No. PCT/US2019/26765, 10 pages.
Bott, et al., “Impact of Smoking on the Metabolic Action of Subcutaneous Regular Insulin in Type 2 Diabetic Patients,” Horm. Metab. Res., vol. 37, 2005, pp. 445-449.
Chase, et at., “The Use of Insulin Pumps With Meal Bolus Alarms in Children With Type 1 Diabetes to Improve Glycemic Control,” Diabetes Carem, vol. 29, No. 5, May 2006, pp. 1012-1015.
“Compare Insulin Pump for Diabetes,” Printed from www.diabetesnet.com/diabetes-technology/insulin-pump-models.php, Jun. 18, 2009, 4 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US09/00107 dated May 4, 2009, 9 pages.
Lehmann, et al., “Combining rule-based reasoning and mathematical modeling in diabetes care,” Artificial Intelligence in Medicine, vol. 6, 1994, pp. 137-160.
Hildebrandt P, “Subcutaneous Absorption of Insulin in Insulin-Dependent Diavetic patients. Influence of Species Physico-Chemical properties of Insulin and Physiological factors,” Danish Medical Bulletin, Aug. 1991, 10 pages.
Plougmann, et al., “DiasNet—a diabetes advisory system for communication and education via the internet,” International Journal of Medical Informatics, vol. 64, 2001, 1 page.
Puckett, et al., “A model for multiple subcutaneous insulin injections developed from individual diabetic patient data,” vol. 269, 1995, p. E1115-E1124.
Smith Medical MD Inc., “Deltec Cozmo, Personalized Insulin Pump, Starting Guide,” http://web.archive.org/web/20041207133223/http://www.cozmore.com/Library/-upload/starting.sub.--guide.sub.--032004.pdf, XP002497833, Dec. 7, 2004, pp. 1-83.
Stapel E., “Converting Between Decimals, Fractions, and Percents,” Purplemath, 2006, 9 pages, Available at http://www.purplemath.com/modules/percents2.htm, 2006.
Trajanoski, et al., “Pharmacokinetic Model for the Absorption of Subcutaneously Injected Soluble Insulin and Monomeric Insulin Analogues,” Biomedizinische Technik, vol. 38, No. 9. Sep. 1, 1993, pp. 224-231.
Wach, et al., “Numerical Approximation of Mathematical Model for Absorption of Subcutaneously Injected Insulin,” Med & Biol. Eng & comput., vol. 33, 1995, pp. 18-23.
Walsh, et al., “Diabetes Technology—Concept 1: Super Bolus, available at Diabetes Technology—Concept 1: Super Bolus” available at http://www.diabetesnet.com/diabetes.sub.--technology/super.sub.--bolus.ph-p&gt, Sep. 17, 2007, 3 pages.
Walsh J., et al., “Select & Test Your Correction Factor,” Pumping Insulin, Fourth Edition, Chapter 13, 2006, 10 Pages.
Walsh J., et al., “Select & Test Your Basal Rates,” Pumping Insulin, Fourth Edition, Chapter 11, 2006, 30 pages.
Walsh J., et al., “Select and Test Your Carb Factor,” Pumping Insulin, Fourth Edition, Chapter 12, 2006, 32 pages.
Walsh J., et al., “Pumping Insulin: Everything you need for Success on a Smart insulin Pump,” Torrey Pines Press, San Diego, ISBN 1-884804-86-1, 2006, 3 pages.
wikipedia.com, “Wikipedia's definition for “basal rate”,” printed from wikipedia.com on Jun. 12, 2009, 1 page.
Wilinska, et al., “Insulin Kinetics in Type-1 Diabetes: Continuous and Bolus Delivery of Rapid Acting Insulin,” IEEE Transactions on Biomedical Engineering, vol. 52, No. 1, Jan. 2005, pp. 3-12.
EP Application No. 19785688.3, Extended EP Search Report dated Nov. 22, 2021, 11 pages.
Related Publications (1)
Number Date Country
20190307952 A1 Oct 2019 US
Provisional Applications (1)
Number Date Country
62655516 Apr 2018 US